PHARMACOGENETICS OF ANTIDEPRESSANT RESPONSE AND REMISSION: TOWARD GENOTYPE-GUIDED PRESCRIBING IN MAJOR DEPRESSIVE DISORDER

抗抑郁药反应和缓解的药物遗传学：针对重度抑郁症的基因型指导处方

• 批准号: nhmrc : 1127700
• 负责人: Dr Chad Bousman
• 金额: $ 29.04万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/pharmacogenetics-antidepressant-response-depressive-disorder/948043
• 关键词: PHARMACOGENETICS; ANTIDEPRESSANT; RESPONSE; REMISSION; TOWARD

A “one-size fits all” approach to antidepressant pharmacotherapy in depression is suboptimal. Current technology and scientific data support the transition to a personalised approach to antidepressant pharmacotherapy. My research will (1) develop and test genetic based algorithms for their ability to predict antidepressant response and remission and (2) evaluate the clinical validity and utility of currently available algorithms in clinical practice.

一个“一刀切”的方法来抗抑郁药物治疗抑郁症是次优的。目前的技术和科学数据支持向个性化抗抑郁药物治疗方法的过渡。我的研究将（1）开发和测试基于遗传的算法预测抗抑郁药反应和缓解的能力，（2）评估目前可用算法在临床实践中的临床有效性和实用性。